Skip to main content

Arcutis Biotherapeutics, Inc.

corporate_fare Company Profile

Arcutis Biotherapeutics, Inc.

ARQT·NASDAQ·Life Sciences·CIK 0001787306

Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and sells treatments for dermatological diseases with significant unmet medical needs. The company's portfolio includes topical and systemic treatments designed for immune-mediated dermatological diseases and conditions. Arcutis focuses on validated biological targets and uses its drug development platform and dermatology expertise to create differentiated products that aim to improve upon existing therapies. The company launched its primary product, ZORYVE cream 0.3%, in August 2022. This launch followed initial FDA approval for treating plaque psoriasis, including psoriasis in intertriginous areas, in individuals 12 years of age or older. ZORYVE cream 0.3% is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. It is approved for once-daily topical treatment of mild, moderate, and severe plaque psoriasis without limitations on location or duration of use. In October 2023, the FDA approved an expanded indication for ZORYVE cream 0.3% for plaque psoriasis in individuals down to 6 years of age. In November 2025, the FDA accepted a supplemental New Drug Application (sNDA) to potentially expand ZORYVE cream 0.3%'s indication for plaque psoriasis in children down to 2 years of age, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026. Arcutis expanded commercially outside the United States in June 2023, following Health Canada's approval of ZORYVE cream 0.3% for treating plaque psoriasis in individuals 12 years of age or older. In February 2026, Health Canada accepted a Supplement to a New Drug Submission (SNDS) for ZORYVE cream 0.3% for individuals down to 2 years old.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for ARQT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for ARQT spans 10-Q, 8-K.

Recent high-impact activity:

  • Arcutis Sinks ~20% as Q3 Earnings Miss on Surging SG&A, Guidance Still Raised
  • Arcutis Lifts Full-Year Sales Guidance to $535M-$545M After 45% Q3 Revenue Jump
  • Arcutis 10-Q: Q3 Revenue $143.9M, Nine-Month Profit $12.5M, ATM Upsized to $200M
  • Arcutis Q3 Revenue Jumps 45% to $143.9M, Full-Year Guidance Raised to $535-545M
  • Arcutis Posts 6-Cent Q3 EPS as Stock Sits Near 52-Week High

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$376.07M
Net Income
-$16.14M
Diluted EPS
-$0.13
Op. Cash Flow
-$5.63M
Free Cash Flow
-$6.31M
Gross Profit
$339.38M
Operating Income
-$12.23M
Cash & Equivalents
$42.91M
Total Debt
$108.96M
Debt / Equity
0.58×
Net Margin
-4.3%
Shares Outstanding
123.33M sh
Source: 10-K · filed 2026-02-25 · accession 0001787306-26-000018

Short Interest & Short Volume

7.58 days to cover

FINRA reported short interest of 18,157,145 shares in ARQT as of the October 30, 2026 settlement, a 11.4% decrease from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 69.5% of ARQT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)18,157,145 shares as of October 30, 2026
Change vs prior period▼ 11.4%
Days to cover7.58 at avg daily volume of 2,396,041
Daily short volume (FINRA facilities)69.5% of 323,730 shares on November 20, 2026
5-day average short volume66.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ARQT, detected from its recent SEC filings · based on capital-structure filings through 2026-11-04.

1 recent capital raise

ATM Prospectus Supplement Filed · No Shares Sold Under Program

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$26.4 +0.15% today
52-week range · as of 2026-11-04 $19.3 – $34.8
Market cap
$3.33B
Volume
1.3M (0.6× avg)
3-mo avg 2.3M
Live data · 2026-11-21 17:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ARQT - Latest Insights

ARQT
Nov 05, 2026, 11:52 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $26.96
Real-time Price: $26.40 info
Change: -$0.560 (-2%) info
Market Cap: $3.333B info
ARQT
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.00
Real-time Price: $26.40 info
Change: -$2.60 (-9%) info
Market Cap: $3.333B info
ARQT
Nov 04, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.25
Real-time Price: $26.40 info
Change: -$4.85 (-16%) info
Market Cap: $3.333B info
ARQT
Nov 04, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.30
Real-time Price: $26.40 info
Change: -$5.90 (-18%) info
Market Cap: $3.333B info
ARQT
Nov 04, 2026, 4:00 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $34.23
Real-time Price: $26.40 info
Change: -$7.83 (-23%) info
Market Cap: $3.333B info
ARQT
Aug 20, 2026, 1:38 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $24.92
Real-time Price: $26.40 info
Change: +$1.48 (+6%) info
Market Cap: $3.333B info
ARQT
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $25.21
Real-time Price: $26.40 info
Change: +$1.19 (+5%) info
Market Cap: $3.333B info
ARQT
Aug 05, 2026, 4:21 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.86
Real-time Price: $26.40 info
Change: -$3.46 (-12%) info
Market Cap: $3.333B info
ARQT
Jul 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $27.47
Real-time Price: $26.40 info
Change: -$1.07 (-4%) info
Market Cap: $3.333B info
ARQT
Jun 29, 2026, 7:15 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $27.20
Real-time Price: $26.40 info
Change: -$0.800 (-3%) info
Market Cap: $3.333B info
ARQT
May 06, 2026, 4:08 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $22.74
Real-time Price: $26.40 info
Change: +$3.66 (+16%) info
Market Cap: $3.333B info
ARQT
May 06, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $23.00
Real-time Price: $26.40 info
Change: +$3.40 (+15%) info
Market Cap: $3.333B info
ARQT
Apr 22, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $24.51
Real-time Price: $26.40 info
Change: +$1.89 (+8%) info
Market Cap: $3.333B info
ARQT
Mar 10, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $24.81
Real-time Price: $26.40 info
Change: +$1.59 (+6%) info
Market Cap: $3.333B info
ARQT
Feb 25, 2026, 4:04 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $27.85
Real-time Price: $26.40 info
Change: -$1.45 (-5%) info
Market Cap: $3.333B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets